Literature DB >> 30821595

Cancer incidence and mortality after heart transplantation - A population-based national cohort study.

Salla Jäämaa-Holmberg1,2, Birgitta Salmela1,2, Karl Lemström1,2, Eero Pukkala3,4, Jyri Lommi1.   

Abstract

Background: Cancer is currently one of the most important factors affecting the long-term health and survival of heart transplant patients. Material and methods: We calculated the standardized incidence ratios (SIR) for different cancer sites and the cancer-specific standardized mortality ratio (SMR) by linking a cohort of 479 adult heart transplant recipients transplanted in 1985-2014 (4491.6 person-years of follow-up) with data from the national Finnish Cancer Registry until the end of 2015, and with the data from the Statistics Finland's national registry of causes of death.
Results: A total of 267 cancers occurred in 143 patients (SIR 6.0; 95% confidence interval (CI) 5.3-6.7). The SIR for overall cancer was considerably higher for men (SIR 6.7; 95% CI 5.9-7.5) than for women (1.4; 95% CI 0.6-2.6). Most frequent cancers were non-melanoma skin cancers (basal cell carcinoma 83 cases, squamous cell skin cancer (SCC) 56 cases), followed by Non-Hodgkin lymphoma (NHL) (36 cases), lung cancer (17), cancer of prostate (16) and cancer of kidney (12). SIRs were highest for SCC (51.9; 95% CI 39.2-67.4), lip cancer (47.4; 95% CI 19.1-97.7), cancer of tongue (26.3; 95% CI 7.2-67.4), and NHL (25.7; 95% CI 18.0-35.6). For most cancers, SIRs increased steadily by time since transplantation. Cancer mortality was three times higher for heart transplant recipients than for the population (SMR 3.1; 95% CI 2.1-4.1). Conclusions: Both cancer incidence and mortality are remarkably increased after heart transplantation, with the relative incidence most elevated for SCC, lip and other oral cancers, and for NHL.

Entities:  

Year:  2019        PMID: 30821595     DOI: 10.1080/0284186X.2019.1580385

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  11 in total

1.  Diltiazem as a cyclosporine A-sparing agent in heart transplantation: Benefits beyond dose reduction.

Authors:  Emyal Alyaydin; Holger Reinecke; Izabela Tuleta; Juergen R Sindermann
Journal:  Medicine (Baltimore)       Date:  2022-10-14       Impact factor: 1.817

2.  Influence of renal insufficiency pre-heart transplantation on malignancy risk post-heart transplantation.

Authors:  Stefan Roest; Christianne Struijk; Alina A Constantinescu; Kadir Caliskan; Elsemieke I Plasmeijer; Eric Boersma; Jasper J Brugts; Olivier C Manintveld
Journal:  ESC Heart Fail       Date:  2021-03-28

3.  De-novo malignancies after kidney transplantation: A long-term observational study.

Authors:  Felix A Fröhlich; Fabian Halleck; Lukas Lehner; Eva V Schrezenmeier; Marcel Naik; Danilo Schmidt; Dmytro Khadzhynov; Katharina Kast; Klemens Budde; Oliver Staeck
Journal:  PLoS One       Date:  2020-11-30       Impact factor: 3.240

4.  Risk prediction model for cutaneous squamous cell carcinoma in adult cardiac allograft recipients.

Authors:  Nandini Nair; Zhiyong Hu; Dongping Du; Enrique Gongora
Journal:  World J Transplant       Date:  2021-03-18

5.  Cancer risk in heart or lung transplant recipients: A comprehensive analysis of 21 prospective cohorts.

Authors:  Fan Ge; Caichen Li; Xin Xu; Zhenyu Huo; Runchen Wang; Yaokai Wen; Haoxin Peng; Xiangrong Wu; Hengrui Liang; Guilin Peng; Run Li; Danxia Huang; Ying Chen; Shan Xiong; Ran Zhong; Bo Cheng; Jianfu Li; Jianxing He; Wenhua Liang
Journal:  Cancer Med       Date:  2020-10-13       Impact factor: 4.452

6.  Cancer Risks in Solid Organ Transplant Recipients: Results from a Comprehensive Analysis of 72 Cohort Studies.

Authors:  Zhenyu Huo; Caichen Li; Xin Xu; Fan Ge; Runchen Wang; Yaokai Wen; Haoxin Peng; Xiangrong Wu; Hengrui Liang; Guilin Peng; Run Li; Danxia Huang; Ying Chen; Ran Zhong; Bo Cheng; Shan Xiong; Weiyi Lin; Jianxing He; Wenhua Liang
Journal:  Oncoimmunology       Date:  2020-11-29       Impact factor: 8.110

7.  Characteristics, outcomes, and predictors of de novo malignancy after heart transplantation.

Authors:  Jong-Chan Youn; Darae Kim; In-Cheol Kim; Hye Sun Lee; Jin-Oh Choi; Eun-Seok Jeon; Keith Nishihara; Evan P Kransdorf; David H Chang; Michelle M Kittleson; Jignesh K Patel; Danny Ramzy; Fardad Esmailian; Jon A Kobashigawa
Journal:  Front Cardiovasc Med       Date:  2022-08-08

8.  No significant association between immunosuppression in solid organ transplantation and prostate cancer risk: a meta-analysis of cohort studies.

Authors:  Ji-Ming Bao; Hai-Li Zhu; Guo-Sheng Yang; Peng-Liang Chen; Qiang Dang; Xing-Xing Chen; Kai-Qiang Tang; Yong-Tong Zhu; Xu-Wei Hong; Wan-Long Tan
Journal:  Transl Cancer Res       Date:  2019-06       Impact factor: 1.241

9.  Risk Factors, Treatment and Prognosis of Patients with Lung Cancer after Heart Transplantation.

Authors:  Karsten M Heil; Matthias Helmschrott; Fabrice F Darche; Tom Bruckner; Philipp Ehlermann; Michael M Kreusser; Andreas O Doesch; Wiebke Sommer; Gregor Warnecke; Norbert Frey; Rasmus Rivinius
Journal:  Life (Basel)       Date:  2021-12-04

10.  Cancer risk and mortality after solid organ transplantation: A population-based 30-year cohort study in Finland.

Authors:  Terhi Kristiina Friman; Salla Jäämaa-Holmberg; Fredrik Åberg; Ilkka Helanterä; Maija Halme; Markku O Pentikäinen; Arno Nordin; Karl B Lemström; Timo Jahnukainen; Riikka Räty; Birgitta Salmela
Journal:  Int J Cancer       Date:  2022-02-03       Impact factor: 7.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.